Research Article
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Suitability of Immobilized Systems for Microbiological Degradation of Endocrine Disrupting Compounds
molecules Review Suitability of Immobilized Systems for Microbiological Degradation of Endocrine Disrupting Compounds Danuta Wojcieszy ´nska , Ariel Marchlewicz and Urszula Guzik * Institute of Biology, Biotechnology and Environmental Protection, Faculty of Natural Science, University of Silesia in Katowice, Jagiello´nska28, 40-032 Katowice, Poland; [email protected] (D.W.); [email protected] (A.M.) * Correspondence: [email protected]; Tel.: +48-3220-095-67 Academic Editors: Urszula Guzik and Danuta Wojcieszy´nska Received: 10 September 2020; Accepted: 25 September 2020; Published: 29 September 2020 Abstract: The rising pollution of the environment with endocrine disrupting compounds has increased interest in searching for new, effective bioremediation methods. Particular attention is paid to the search for microorganisms with high degradation potential and the possibility of their use in the degradation of endocrine disrupting compounds. Increasingly, immobilized microorganisms or enzymes are used in biodegradation systems. This review presents the main sources of endocrine disrupting compounds and identifies the risks associated with their presence in the environment. The main pathways of degradation of these compounds by microorganisms are also presented. The last part is devoted to an overview of the immobilization methods used for the purposes of enabling the use of biocatalysts in environmental bioremediation. Keywords: EDCs; hormones; degradation; immobilization; microorganisms 1. Introduction The development of modern tools for the separation and identification of chemical substances has drawn attention to the so-called micropollution of the environment. Many of these contaminants belong to the emergent pollutants class. According to the Stockholm Convention they are characterized by high persistence, are transported over long distances in the environment through water, accumulate in the tissue of living organisms and can adversely affect them [1]. -
Présentation HJ
Conflits d’intérêts Astra-Zeneca, Janssen, Abacus international, Laboratoire ETAP, Institut Pasteur. Dr Hervé JAVELOT Pharmacien PH Etablissement Public de Santé Alsace Nord Service Pharmacie 141 avenue de Strasbourg 67 170 BRUMATH Tél. : 03 88 64 61 70 Fax : 03 88 64 61 58 Mail : [email protected] Perspectives dans la psychopharmacologie de l’anxiété et de la dépression Hervé JAVELOT Etablissement Public de Santé Alsace Nord Perspectives dans la psychopharmacologie de l’anxiété et de la dépression Traitements des troubles anxio-dépressifs. Les perspectives. ◦ L’axe GABAergique…éternellement prometteur ? ◦ L’incontournable théorie « monoaminergique »… ◦ Des théories alternatives à suivre … Traitements des troubles anxio-dépressifs. Contexte : ◦ XXI ème siècle : Le « siècle de la dépression » s’installe ? (Hardeveld et al., 2010) L’« ère de l’angoisse » s’affirme ? (Auden, 1947) ◦ Prévalence au cours de la vie : 16 à 17% pour la dépression, 17 à 18% pour les troubles anxieux Co-morbidité des 2 troubles dans 20 à 40% des cas (Antony, 2011 ; Depping et al., 2010 ; Hardeveld et al., 2010 ; Huppert, 2009) Auden WH (1947). The Age of Anxiety: A Baroque Eclogue. Random House: New York. Hardeveld F, Spijker J, De Graaf R, Nolen WA, Beekman AT. Prevalence and predictors of recurrence of major depressive disorder in the adult population. Acta Psychiatr Scand. 2010;122(3):184-91. Antony MM. Recent advances in the treatment of anxiety disorders. Canadian Psychology 2011;52(1), 10-19. Depping AM, Komossa K, Kissling W, Leucht S. Second-generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev. 2010;(12):CD008120. Huppert JD. Anxiety disorders and depression comorbidity. -
Exploring the Activity of an Inhibitory Neurosteroid at GABAA Receptors
1 Exploring the activity of an inhibitory neurosteroid at GABAA receptors Sandra Seljeset A thesis submitted to University College London for the Degree of Doctor of Philosophy November 2016 Department of Neuroscience, Physiology and Pharmacology University College London Gower Street WC1E 6BT 2 Declaration I, Sandra Seljeset, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I can confirm that this has been indicated in the thesis. 3 Abstract The GABAA receptor is the main mediator of inhibitory neurotransmission in the central nervous system. Its activity is regulated by various endogenous molecules that act either by directly modulating the receptor or by affecting the presynaptic release of GABA. Neurosteroids are an important class of endogenous modulators, and can either potentiate or inhibit GABAA receptor function. Whereas the binding site and physiological roles of the potentiating neurosteroids are well characterised, less is known about the role of inhibitory neurosteroids in modulating GABAA receptors. Using hippocampal cultures and recombinant GABAA receptors expressed in HEK cells, the binding and functional profile of the inhibitory neurosteroid pregnenolone sulphate (PS) were studied using whole-cell patch-clamp recordings. In HEK cells, PS inhibited steady-state GABA currents more than peak currents. Receptor subtype selectivity was minimal, except that the ρ1 receptor was largely insensitive. PS showed state-dependence but little voltage-sensitivity and did not compete with the open-channel blocker picrotoxinin for binding, suggesting that the channel pore is an unlikely binding site. By using ρ1-α1/β2/γ2L receptor chimeras and point mutations, the binding site for PS was probed. -
Prevention Or Amelioration of Autism-Like Symptoms in Animal Models: Will It Bring Us Closer to Treating Human ASD?
International Journal of Molecular Sciences Review Prevention or Amelioration of Autism-Like Symptoms in Animal Models: Will it Bring Us Closer to Treating Human ASD? Asher Ornoy 1,* , Liza Weinstein-Fudim 1 and Zivanit Ergaz 1,2 1 Laboratory of Teratology, Department of Medical Neurobiology, Hebrew University Hadassah Medical School, Jerusalem 9112001, Israel; [email protected] 2 Neonatology Department, Hadassah Hebrew University Medical Center, Jerusalem 9112001, Israel; [email protected] * Correspondence: [email protected]; Tel.: +972-2-6758329 Received: 17 February 2019; Accepted: 23 February 2019; Published: 1 March 2019 Abstract: Since the first animal model of valproic acid (VPA) induced autistic-like behavior, many genetic and non-genetic experimental animal models for Autism Spectrum Disorder (ASD) have been described. The more common non-genetic animal models induce ASD in rats and mice by infection/inflammation or the prenatal or early postnatal administration of VPA. Through the establishment of these models, attempts have been made to ameliorate or even prevent ASD-like symptoms. Some of the genetic models have been successfully treated by genetic manipulations or the manipulation of neurotransmission. Different antioxidants have been used (i.e., astaxanthin, green tea, piperine) to reduce brain oxidative stress in VPA-induced ASD models. Agents affecting brain neurotransmitters (donepezil, agmatine, agomelatine, memantine, oxytocin) also successfully reduced ASD-like symptoms. However, complete prevention of the development of symptoms was achieved only rarely. In our recent study, we treated mouse offspring exposed on postnatal day four to VPA with S-adenosine methionine (SAM) for three days, and prevented ASD-like behavior, brain oxidative stress, and the changes in gene expression induced by VPA. -
Pheromone Advantage Review Examining Dr. Virgil Amend's
Pheromone Advantage: Review Examining Dr. Virgil Amend’s Pheromone Cologne Product Released Pheromone Advantage reviews have been popping up all over the Internet and GentlemensUniversity.com reveals the truth about this cologne that claims it makes it so much easier to attract the opposite gender. (PRWEB) February 08, 2014 Pheromone Advantage that claims people can amplify their sexual appeal to the opposite sex and even intimidate others from the same sex by simply spritzing some of the pheromone cologne on has caught the attention of GentlemensUniversity.com’s Stan Stevenson, prompting an investigative review. “Our Pheromone Advantage review shows that it is a pheromone cologne product developed by Dr. Virgil Amend. It triggers emotions and sexual attraction without the opposite sex ever realizing that they are actually being influenced by pheromones,” reports Stevenson. “Most other pheromone scents contain very small amounts of pheromones, certainly not enough to have much of an impact on the opposite sex. Pheromone Advantage comes in two variants, one meant to attract men, and the other for targeting women. Each variant is formulated accordingly with the correct pheromones with a large enough concentration, so they can’t easily be washed away or masked.” Pheromone Advantage for attracting women is formulated with Androstenone, Androstenol, and Androstadienone. Produced by both men and women, although Androstenone is considered to be a predominantly male pheromone, it gives off a good strong vibe akin to that of an alpha male. Androstenol helps the wearer seem less intimidating and more approachable, and helps elevate the mood of a woman. Pheromone Advantage for attracting men contains Copulins, Estratetraenol, and Androstenol. -
Antinociceptive Activity of a Neurosteroid Tetrahydrodeoxycorticosterone (5Cx-Pregnan-3Cx-21-Diol-20-One) and Its Possible Mechanism(S) of Action
Indian Journal of Experimental Biology Vol. 39, December 2001, pp. 1299-1301 Antinociceptive activity of a neurosteroid tetrahydrodeoxycorticosterone (5cx-pregnan-3cx-21-diol-20-one) and its possible mechanism(s) of action P K Mediratta, M Gambhir, K K Sharma & M Ray Department of Pharmacology, University College of Medical Sciences and GTB Hospital, Delhi II 0095, India Fax: 91-11-2299495; E-mail: [email protected]/[email protected] Received 9 Apri/2001; revised 2 July 2001 The present study investigates the effects of a neurosteroid tetrahydrodeoxycorticosterone (5a-pregnan-3a-21-diol-20- one) in two experimental models of pain sensitivity in mice. Tetrahydrodeoxycorticosterone (2.5, 5 mg!kg, ip) dose dependently decreased the licking response in formalin test and increased the tail flick latency (TFL) in tail flick test. Bicuculline (2 mg/kg, ip), a GABAA receptor antagonist blocked the antinociceptive effect of tetrahydrodeoxy corticosterone in TFL test but failed to modulate licking response in formalin test. Naloxone (I mglkg, ip), an opioid antagonist effectively attenuated the analgesic effect of tetrahydrodeoxycorticosterone in both the models. Tetrahydrodeoxycorticosterone pretreatment potentiated the anti nociceptive response of morphine, an opioid compound and nimodipine, a calcium channel blocker in formalin as well as TFL test. Thus, tetrahydrodeoxycorticosterone exerts an analgesic effect, which may be mediated by modulating GABA-ergic and/or opioid-ergic mechanisms and voltage-gated calcium channels. It is now well known that some of the steroids like Allopregnanolone has been shown to exhibit progesterone can act on central nervous system (CNS) antinociceptive effect against an aversive thermal to produce a number of endocrine and behavioral stimulus 10 and in a rat mechanical visceral pain 11 effects. -
WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 36/84 (2006.01) A61K 31/5513 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/045 (2006.01) A61P 31/22 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/522 (2006.01) A61K 45/06 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/NL20 14/050780 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (22) International Filing Date: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 13 November 2014 (13.1 1.2014) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (25) Filing Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/903,430 13 November 2013 (13. 11.2013) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: RJG DEVELOPMENTS B.V. -
Effect of Isopregnanolone on Rapid Tolerance to the Anxiolytic Effect of Ethanol Influência Da Isopregnenolona Na Tolerância R
18 ORIGINAL ARTICLE Effect of isopregnanolone on rapid tolerance to the anxiolytic effect of ethanol Influência da isopregnenolona na tolerância rápida ao efeito ansiolítico do etanol Thaize Debatin,1 Adriana Dias Elpo Barbosa2 Original version accepted in Portuguese Abstract Objective: It has been shown that neurosteroids can either block or stimulate the development of chronic and rapid tolerance to the incoordination and hypothermia caused by ethanol consumption. The aim of the present study was to investigate the influence of isopregnanolone on the development of rapid tolerance to the anxiolytic effect of ethanol in mice. Method: Male Swiss mice were pretreated with isopregnanolone (0.05, 0.10 or 0.20 mg/kg) 30 min before administration of ethanol (1.5 g/kg). Twenty-four hours later, all animals we tested using the plus-maze apparatus. The first experiment defined the doses of ethanol that did or did not induce rapid tolerance to the anxiolytic effect of ethanol. In the second, the influence of pretreatment of mice with isopregnanolone (0.05, 0.10 or 0.20 mg/kg) on rapid tolerance to ethanol (1.5 g/kg) was studied. Conclusions: The results show that pretreatment with isopregnanolone interfered with the development of rapid tolerance to the anxiolytic effect of ethanol. Keywords: Ethanol; Drug tolerance; Anti-anxiety agents; Mice; Alcoholism Resumo Objetivo: Estudos prévios têm mostrado que os neuroesteróides podem bloquear ou estimular o desenvolvimento da tolerância rápida e crônica aos efeitos de incoordenação e hipotermia produzidos pelo etanol. O objetivo do presente estudo foi investigar a influência da isopregnenolona sobre o desenvolvimento da tolerância rápida ao efeito ansiolítico do etanol em camundongos. -
NMDA Receptors Containing the Glun2d Subunit Control Neuronal Function in the Subthalamic Nucleus
The Journal of Neuroscience, December 2, 2015 • 35(48):15971–15983 • 15971 Cellular/Molecular NMDA Receptors Containing the GluN2D Subunit Control Neuronal Function in the Subthalamic Nucleus X Sharon A. Swanger,1* Katie M. Vance,1* Jean-Franc¸ois Pare,3 Florence Sotty,4 Karina Fog,4 Yoland Smith,2,3 and X Stephen F. Traynelis1 1Department of Pharmacology and 2Department of Neurology, Emory University School of Medicine, Atlanta, Georgia 30322, 3Yerkes National Primate Research Center and Morris K. Udall Center of Excellence for Parkinson’s Disease Research, Emory University, Atlanta, Georgia 30329, and 4H. Lundbeck A/S, Division of Neurodegeneration and Biologics, Ottiliavej 9, DK-2500 Valby, Denmark The GluN2D subunit of the NMDA receptor is prominently expressed in the basal ganglia and associated brainstem nuclei, including the subthalamic nucleus (STN), globus pallidus, striatum, and substantia nigra. However, little is known about how GluN2D-containing NMDA receptors contribute to synaptic activity in these regions. Using Western blotting of STN tissue punches, we demonstrated that GluN2D is expressed in the rat STN throughout development [age postnatal day 7 (P7)–P60] and in the adult (age P120). Immunoelectron microscopy of the adult rat brain showed that GluN2D is predominantly expressed in dendrites, unmyelinated axons, and axon terminals within the STN. Using subunit-selective allosteric modulators of NMDA receptors (TCN-201, ifenprodil, CIQ, and DQP-1105), we provide evidence that receptors containing the GluN2B and GluN2D subunits mediate responses to exogenously applied NMDA and glycine, as well as synaptic NMDA receptor activation in the STN of rat brain slices. EPSCs in the STN were mediated primarily by AMPA and NMDA receptors and GluN2D-containing NMDA receptors controlled the slow deactivation time course of EPSCs in the STN. -
Stems for Nonproprietary Drug Names
USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol -
Epipregnanolone and a Novel Synthetic Neuroactive Steroid Reduce Reduce Alcohol Self- Administration in Rats
University of Texas at El Paso From the SelectedWorks of Laura Elena O'Dell 2005 Epipregnanolone and a novel synthetic neuroactive steroid reduce reduce alcohol self- administration in rats. Laura O'Dell, University of Texas at El Paso Available at: https://works.bepress.com/laura_odell/23/ Pharmacology, Biochemistry and Behavior 81 (2005) 543 – 550 www.elsevier.com/locate/pharmbiochembeh Epipregnanolone and a novel synthetic neuroactive steroid reduce alcohol self-administration in rats L.E. O’Della,b, R.H. Purdya,c,d, D.F. Coveye, H.N. Richardsona, M. Robertoa, G.F. Kooba,* aDepartment of Neuropharmacology, The Scripps Research Institute, CVN-7, 10550 North Torrey Pines Rd., La Jolla, CA, 92037, USA bDepartment of Psychology, The University of Texas at El Paso, El Paso, TX, USA cDepartment of Psychiatry, University of California San Diego, La Jolla, CA, USA dDepartment of Veterans Affairs Medical Center and Veterans Medical Research Foundation, San Diego, CA, USA eDepartment of Molecular Biology and Pharmacology, Washington University School of Medicine, St Louis, MO, USA Received 6 September 2004; received in revised form 14 March 2005; accepted 31 March 2005 Available online 9 June 2005 Abstract This study was designed to compare the effects of several neuroactive steroids with varying patterns of modulation of g-aminobutyric acid (GABA)A and NMDA receptors on operant self-administration of ethanol or water. Once stable responding for 10% (w/v) ethanol was achieved, separate test sessions were conducted in which male Wistar rats were allowed to self-administer ethanol or water following pre-treatment with vehicle or one of the following neuroactive steroids: (3h,5h)-3-hydroxypregnan-20-one (epipregnanolone; 5, 10, 20 mg/kg; n =12), (3a,5h)-20-oxo-pregnane-3-carboxylic acid (PCA; 10, 20, 30 mg/kg; n =10), (3a,5h)-3-hydroxypregnan-20-one hemisuccinate (pregnanolone hemisuccinate; 5, 10, 20 mg/kg; n =12) and (3a,5a)-3-hydroxyandrostan-17-one hemisuccinate (androsterone hemisuccinate; 5, 10, 20 mg/kg; n =11). -
Download Product Insert (PDF)
PRODUCT INFORMATION Epipregnanolone Item No. 34295 CAS Registry No.: 128-21-2 O Formal Name: (5β)-3β-hydroxy-pregnan-20-one Synonyms: NSC 21450, 5β-Pregnan-3β-ol-20-one MF: C21H34O2 FW: 318.5 H Purity: ≥98% H H Supplied as: A solid Storage: -20°C HO Stability: ≥2 years H Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Epipregnanolone is supplied as a solid. A stock solution may be made by dissolving the epipregnanolone in the solvent of choice, which should be purged with an inert gas. Epipregnanolone is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of epipregnanolone in ethanol is approximately 5 mg/ml and approximately 30 mg/ml in DMSO and DMF. Description Epipregnanolone is a neurosteroid and an active metabolite of the steroid hormone pregnenolone (Item No. 19864).1 It is enzymatically formed from prognenolone via the intermediates progesterone (Item No. 15876) and 5β-dihydroprogesterone in the placenta.2 Epipregnanolone inhibits spontaneous 3 contractions in myometrial strips isolated from at-term pregnant women (IC50 = 156 µM). Epipregnanolone (10 and 20 mg/kg) decreases operant alcohol self-administration in rats.4 Maternal plasma levels of epipregnanolone increase over the duration of pregnancy. References 1. Prince, R.J. and Simmonds, M.A. 5β-pregnan-3β-ol-20-one, a specific antagonist at the neurosteroid site of the GABAA receptor-complex. Neurosci. Lett. 135(2), 273-275 (1992). 2. Hill, M., Cibula, D., Havlíkova, H., et al. Circulating levels of pregnanolone isomers during the third trimester of human pregnancy.